

REVIEW

Delineating nuclear reprogramming

Jolene Ooi^{1,2}, Pentao Liu¹✉

¹ Wellcome Trust Sanger Institute, Hinxton CB10 1SA, United Kingdom

² Agency for Science, Technology and Research, Singapore 138632, Singapore

✉ Correspondence: pl2@sanger.ac.uk

Received January 1, 2012 Accepted February 4, 2012

ABSTRACT

Nuclear reprogramming is described as a molecular switch, triggered by the conversion of one cell type to another. Several key experiments in the past century have provided insight into the field of nuclear reprogramming. Previously deemed impossible, this research area is now brimming with new findings and developments. In this review, we aim to give a historical perspective on how the notion of nuclear reprogramming was established, describing main experiments that were performed, including (1) somatic cell nuclear transfer, (2) exposure to cell extracts and cell fusion, and (3) transcription factor induced lineage switch. Ultimately, we focus on (4) transcription factor induced pluripotency, as initiated by a landmark discovery in 2006, where the process of converting somatic cells to a pluripotent state was narrowed down to four transcription factors. The conception that somatic cells possess the capacity to revert to an immature status brings about huge clinical implications including personalized therapy, drug screening and disease modeling. Although this technology has potential to revolutionize the medical field, it is still impeded by technical and biological obstacles. This review describes the effervescent changes in this field, addresses bottlenecks hindering its advancement and in conclusion, applies the latest findings to overcome these issues.

KEYWORDS nuclear reprogramming, naïve pluripotency

INTRODUCTION

Nuclear reprogramming is depicted by the transition between distinct cell types introduced by switches in gene patterns. The conception of this phenomenon evolved through the

establishment of several experimental milestones and has received heightened interest in the past decades (Fig. 1).

Cellular plasticity is exemplified in nature by a fertilized egg. The notion of its ability to develop into three germ layers and form an entire organism was conceived and described by von Baer, Rathke, and Pander in the 1820s (Pander, 1817; von Baer, 1828). Exploration of these ideas led to the conclusions by Weismann and Roux that development occurred in a unilateral fashion where germ cells are the only cells capable of hereditary potential and somatic cells received permanent genetic modifications, rendering them wedged to perform limited functions. To support his claim, Roux showed that ablation of one cell of the two-cell frog embryo resulted in incomplete development (Roux, 1888). This was quickly confounded by Driesch and Spemann who demonstrated that isolation of single cells from sea urchin (Driesch, 1894) and newt embryos (Spemann, 1928) culminated in the development of complete larvae. However, this did not invalidate the proposal that cells accumulate mutations during differentiation.

The paradigm shift began in 1952 when Briggs and King successfully transplanted a nucleus from a *Rana pipiens* embryo into an enucleated oocyte to produce adult organisms (Briggs and King, 1952). However, a later study by the pair revealed that endoderm nuclei from an early tail-bud stage resulted in arrest at blastula gastrula and early-neurula stages (King and Briggs, 1955). Surprisingly, when similar experiments were carried out in *Xenopus laevis*, nuclei from terminally differentiated intestinal epithelial cells were successfully transplanted into irradiated oocytes and developed into fertile male and female frogs (Gurdon, 1962b). This seminal discovery ignited a series of studies and sculpted the views of nuclear reprogramming as we know it today. In this review, we give a historical perspective on the metamorphosis of this field through the description of various approaches to nuclear reprogramming, and subsequently focus on the landmark discovery of transcription factor driven induced




Figure 1. Timeline showing milestones contributing to the conception of vertebrate developmental biology and the initiation of nuclear reprogramming.

pluripotency. We will highlight the dynamic evolution of this branch of cell manipulation and examine mechanistic insights into this phenomenon. In conclusion, we aim to discuss potential applications of this new technology, coupled to its future direction.

SOMATIC CELL NUCLEAR TRANSFER

The ability to transplant a nucleus from a differentiated cell into an oocyte to produce viable fertile offspring triggered huge repercussions as it portrayed similar genomic content between oocytes and somatic cells. Fraught with scepticism at the beginning, the experiments were successfully repeated across species. Rising in popularity, this process of transplanting a donor nucleus into an oocyte has now been termed somatic cell nuclear transfer (SCNT).

As described above, the first instance of SCNT was exhibited in *Xenopus laevis* (Gurdon et al., 1958; Gurdon, 1962a, 1962b). Intestinal epithelium cells of feeding tadpoles which correspond to terminally differentiated endoderm cells gave rise to normal feeding tadpoles at a frequency of 1.5% when transplanted into unfertilized oocytes. This was noticeably lower than nuclear transfers from the blastula and gastrula endoderm which led to a proportion of 36% feeding tadpoles. Interestingly, serial transplantations of intestine nuclei which promoted abnormal development after the first transfer could support the formation of normal feeding tadpoles, suggesting that disparities in efficiencies between differentiated and embryonic nuclei were partially explained by non-genetic causes such as technical limitations and incompatible mitotic properties. Collectively, first and serial transplantations, in concert with grafts, generated functional tadpoles at a frequency of 30% (Gurdon, 1962b; Byrne et al., 2003).

Shortly after came reports of successful transplantations of nuclei from a spectrum of cell origins, such as kidney, lung and skin (Laskey and Gurdon, 1970; Gurdon et al., 1975). Non-dividing erythrocytes from *Rana pipiens* were demonstrated to produce normal larvae upon serial transplantations (DiBerardino and Hoffner, 1983). Nuclear transfer from myotomes could also effectively produce swimming tadpoles at a frequency of 2% (Gurdon et al., 1984). Transcription of muscle differentiation markers ceased upon entry into the oocyte and re-activated once gastrulation occurred. Taken together, these studies suggest that the chemical milieu in the oocyte is able to perturb the transcriptional machinery of the donor cell and reverse its differentiation status.

Alternatively, SCNT can be performed using oocytes in their first meiotic prophase (Byrne, 2003). This manipulation results in the swelling of the cell due to a stark increase in mRNA synthesis. DNA replication is reversely synchronized and pauses, contrary to the use of oocytes in the second meiotic metaphase which leads to multiple rounds of cell division and little transcription. Although mechanistically dis-

tinct, this reaffirms the intrinsic ability of the oocyte to influence the donor cell nucleus.

Concurrent to the described experiments, other groups ventured away from amphibians. Using one-cell mouse embryos as donor and host, adult mice were generated at a success ratio of 13% (McGrath and Solter, 1983). In contrast, transplantation of nuclei from tail-tip fibroblasts plunged the reprogramming efficiency to 0.5%. Mirroring this phenomenon in sheep, Willadsen demonstrated the ability to produce cloned lambs by transplanting a nucleus of an 8-cell embryo to an enucleated oocyte (Willadsen, 1986). Mammary gland cell nuclei were also competent to produce adult fertile female sheep, albeit at a low efficiency of 0.2% (Wilmut et al., 1997).

Several attempts have been made with the use of human oocytes. Injection of donor nuclei into enucleated oocytes gave rise to blastocysts at low frequencies (Stojkovic et al., 2005; Hall et al., 2007; French et al., 2008). Low reprogramming efficiency was alleviated by leaving the nuclei of the oocyte intact (Noggle et al., 2011), leading to the successful development of blastocysts. The inner cell mass was stable in culture and triploid in karyotype, with one set of diploid chromosomes from the somatic nucleus and one set of haploid chromosomes from the oocyte. Competent in producing teratomas consisting of cell types representative of all three germ layers, these cells display similar transcriptional patterns to pluripotent stem cells derived from *in vitro* fertilized blastocysts.

The findings from SCNT experiments present evidence that somatic cells encompass the capacity to return to pluripotency and can be evaluated in two ways. First, cells which have veered away from pluripotency require strict conditions for reprogramming. Second, the egg naturally contains factors which dominate the performance of the somatic nucleus. Stripping the composition of the egg would allow us to comprehend the intricacies that trigger rapid dedifferentiation. To this end, histones 1 and B4 and the Tet proteins have been illustrated to play roles in the oocyte and male pronucleus, highlighting the importance of epigenetic remodeling interactions during reprogramming (Teranishi et al. 2004; Gao et al., 2004; Becker et al., 2005; Jullien et al., 2010; Maki et al., 2010; Inoue and Zhang, 2011; Wu and Zhang, 2011).

EXPOSURE TO CELL EXTRACTS AND CELL FUSION

Re-illustrating the innate ability of the chemical milieu within an oocyte to instigate transcriptional alteration, introduction of cytoplasmic contents from *Xenopus laevis* oocytes and early embryos have been described to elicit the expression of pluripotency markers in human somatic cells (Hansis et al., 2004). This capacity extended till late blastula-stages where extracts were now inhibitory to reprogramming. Human embryonic kidney cells incubated with embryonic carcinoma cell extracts for a mere hour also resulted in transcriptional acti-

vation and partial demethylation of pluripotency genes within a week (Flasza et al., 2003; Taranger et al., 2005; Freberg et al., 2007).

Corroborating these observations, cell fusions between human lymphocytes and mouse embryonic stem (ES) cells have been competent in triggering the reactivation of Oct4. However, the level of transcriptional induction was < 1% compared to human ES cells (Pereira et al., 2008). The capacity of cell fusion induced reprogramming has been further exemplified through the combination of male ES cells and female thymocytes. Resulting heterokaryons expressed pluripotency genes and reactivated the silent X chromosome (Tada et al., 2001). In addition, spontaneous fusion between mouse neural progenitors and mouse ES cells led to the silencing of neural markers (Ying et al., 2002). Replicated in human cells, human ES cells fused to human foreskin fibroblasts generated hybrid pluripotent cells that exhibited the capacity to develop into three germ layers (Cowan et al., 2005). In general, cell fusion experiments displayed trends analogous to SCNT. First, terminally differentiated cells were more demanding to transform. Second, cell fusion leads to rapid reprogramming, where genes are expressed within two days and independent of DNA replication (Pereira et al., 2008; Do and Scholer, 2010). Despite success in generating pluripotent stem cells, reprogramming through cell fusion is inefficient (~1%), and creates a bottleneck during the purification of stable hybrids for analysis. Introduction of selection markers in the two starting populations can overcome this problem, but does not alleviate the eventual low population of reprogrammed cells.

Apart from establishing pluripotency, other cell types have also been successfully reprogrammed through cell fusion. Stemming from early experiments, heterokaryons between erythrocytes from a mature hen and HeLa cells have been described to swell in size and prompt transcriptional activity in terminally differentiated erythrocytes, reminiscent of the observations in SCNT (Harris, 1965; Harris et al., 1966). Surprisingly, the combination of human amniotic cells and mouse muscle cells triggered the expression of genes specific to muscle cells, albeit the naïve nature of amniotic cells (Blau et al., 1983). This draws attention to inherent factors in somatic cells that safeguard the integrity and lineage of the cell. Besides sharing similarities to SCNT, it is useful to note that cell fusion encompasses unique qualities such as the ability to generate heterokaryons using multiple cell-nuclei. As a result, gene dosage influences the reprogramming efficiencies and the presence of the dominant nuclei in more than two fold will delay transcriptional activation (Pavlati and Blau, 1986).

TRANSCRIPTION FACTOR INDUCED LINEAGE SWITCH

It is evident from cell fusion experiments that there are specific components within each branch of cell lineage, shielding

it from external influences and guarding its designed function. These intrinsic cell specific properties can be harnessed to redirect differentiation signals. Using observations that DNA demethylating agent, 5-azacytidine (AZA) enables efficient reprogramming into muscle lineage (Chiu and Blau, 1985), Weintraub and colleagues identified MyoD as a master regulator of myogenesis, and its ectopic expression forced recipient non-muscle cells to convert into myocytes (Weintraub et al., 1989). Although cells from three germ layers were successfully reprogrammed, starting material originating from the mesoderm was effectively converted, whereas cells from endoderm and ectoderm lineages retained their original gene signatures. This suggests the necessity of additional factors to induce a complete reform of the pre-existing gene expression profile.

To reinforce this notion, transdifferentiation has been described in a natural setting. Glucagon-producing α -cells have been reported to transform into pancreatic insulin-producing β -cells upon a diphtheria toxin insult (Thorel et al., 2010) and pigmented epithelial cells in a newt can regenerate its eye lens when removed (Tsonis and Del Rio-Tsonis, 2004). Time-lapse observation of cultured endothelial sheet colonies revealed their capacity to disengage their tight junctions, round up and begin to display erythroid and monocytic hematopoietic antigens (Eilken et al., 2009).

Intuitively, forced expression of transcription factors that naturally occur during developmental programs can incite lineage switches. As described above, expression of MyoD can redirect non-muscle cells into the muscle lineage (Weintraub et al., 1989). In addition, overexpression of adipocyte-specific nuclear hormone receptor, peroxisome proliferator-activated receptor (PPAR) γ 2, triggers adipogenesis in fibroblasts (Tontonoz et al., 1994). Although single genetic factors have been described to control cell fate in adipocytes and myocytes, dermal fibroblasts require a combination of Gata4, Mef2c and Tbx5 to be converted into cardiomyocytes (Ieda et al., 2010). Likewise, ectopic expression of separate sets of transcription factors has successfully triggered transdifferentiation of dermal fibroblasts into neuron-like, blood progenitors, insulin secreting β -cells and brown adipose cells (Zhou et al., 2008; Kajimura et al., 2009; Szabo et al., 2010; Vierbuchen et al., 2010). Further exploration in the realm of lineage switching has placed emphasis on the importance of spatial, temporal and quantitative control of transcription factor expression in the generation of an array of cell types (Kulesa et al., 1995; Xie et al., 2004; Iwasaki et al., 2006; Laiosa et al., 2006).

Lineage switching mimics the acquisition of pluripotency via SCNT and cell fusion closely. First, cells which have climbed the differentiation ladder face more roadblocks during reprogramming (Chickarmane et al., 2009). Second, lineage switch occurs without the need for cell division. Markers of progenitor cells are often not detected, suggesting that reprogramming may occur in a direct fashion without the

presence of an undifferentiated intermediate (Thorel et al., 2010). However, this does not exclude the possibility of a transient intermediate state.

TRANSCRIPTION FACTOR INDUCED PLURIPOTENCY

The ability of transcription factors to impose a lineage switch suggests that the right cocktail of factors would be able to erase all differentiation marks in somatic cells, driving the cell to pluripotency. In 2006, a seminal discovery by Takahashi and Yamanaka illuminated the capacity of four transcription factors, Oct4, c-Myc, Klf4, and Sox2, to transform mouse embryonic fibroblasts into cells that were similar to ES cells and disparate from their original somatic identity. These cells were able to differentiate into three germ layers when injected into immune-compromised mice, portraying its pluripotent potential.

Shortly after, the phenomenon was replicated in human fibroblasts (Takahashi et al., 2007). Concurrently, an independent study reported the generation of human ES-like cells through a discrete set of genes, Oct4, Sox2, Nanog, and Lin28 (Yu et al., 2007). These groundbreaking discoveries indicated that mere four genes can elicit pluripotency, igniting a surge of interest in this sphere of reprogramming (Fig. 2). For the ease of nomenclature, these cells have since been termed as induced pluripotent stem (iPS) cells.

Several refinements have been made to the generation of iPS cells since its inception. This includes the use of surrogate gene delivery tools, encompassing polycistronic lentiviruses, piggyBac mediated transposition and non-integrating approaches such as adenoviruses, Sendai viruses, episomal DNA, repeated transfections of mRNA or plasmid DNA and purified proteins (Okita et al., 2008; Stadtfeld et al., 2008; Carey et al., 2009; Fusaki et al., 2009; Kim et al., 2009a; Sommer et al., 2009; Woltjen et al., 2009; Yu et al., 2009; Yusa et al., 2009; Zhou et al., 2009; Warren et al., 2010). Albeit the low efficiency of producing iPS cells, the employment of non-integrating methods allows the generation of colonies which are completely free of exogenous material. Additional selection markers have also been established to allow the distinction between fully and partially reprogrammed cells (Okita et al., 2007; Maherali et al., 2007; Wang et al., 2011b).

To illustrate the robustness of the protocol, somatic cells originating from the three germ layers have been described to be pliable to reprogramming (Aasen et al., 2008; Aoi et al., 2008; Hanna et al., 2008; Shi et al., 2008). In addition, iPS cells from an array of organisms, including pigs, monkeys and rats, have also been achieved (Liu et al., 2008; Esteban et al., 2009; Liao et al., 2009). Akin to SCNT and cell fusion experiments, terminally differentiated cells have been proven difficult to reprogram (Hanna et al., 2008). Cell types which possess high intrinsic expression of certain factors negotiate

the need for the complete set of reprogramming cocktail (Giorgetti et al., 2009; Kim et al., 2009b, 2009c; Tsai et al., 2010). Overall, these studies display the inherent ability of a spectrum of somatic cell types to revert to its pluripotent state. However, this technology is still in its infancy and harbours many unknowns. To address our lack of knowledge on the reprogramming process, it is crucial to begin elucidating the mechanisms behind the induction of pluripotency. There are several approaches which lead us to unravel its molecular circuitry and will be discussed below.

Molecular mechanisms behind the initial set of four reprogramming factors

Before we endeavour to expand our knowledge of the reprogramming process, it is crucial to understand the roles undertaken by each of the four transcription factors. Naturally present in ES cells, these transcription factors instigate a cascade of molecular events that preserve the functional integrity of the ES cells (Nichols et al., 1998; Avilion et al., 2003; Loh et al., 2006).

Oct4 and Sox2 are principal regulators of the transcriptional network in ES cells and act in concert with Nanog to activate pluripotency-associated elements (Boyer et al., 2005; Masui et al., 2007; Kim et al., 2008). Under tight regulation, deregulation of Oct4 and Sox2 expression levels will lead to differentiation of ES cells (Nichols et al., 1998; Niwa et al., 2000; Tomioka et al., 2002; Chew et al., 2005; Kopp et al., 2008).

Klf4 belongs to the family of Kruppel-like factors which display functional redundancy among family members. Occupying genomic sites similar to the Oct4-Sox2-Nanog cluster (Jiang et al., 2008), the Klf family has been described to act downstream of Oct4, p53 and leukemia inhibitory factor (LIF)/Stat pathways (Rowland et al., 2005; Hall et al., 2009).

c-Myc is a helix-loop-helix/leucine zipper transcription factor that mediates pleiotropic cellular functions including metabolism, cell cycle, splicing, translation, and oncogenic transformation (Klein, 1983; Kim et al., 2008; Sridharan et al., 2009). It has been implicated in the transcriptional elongation in ES cells (Rahl et al., 2010) and shares similar genetic targets with other pluripotency associated transcription factors (Chen et al., 2008; Kim et al., 2008; Dejosez et al., 2008). In ES cells, c-Myc resembles Klf4, acting in the LIF/Stat pathway (Cartwright et al., 2005) and opposing anti-proliferative properties of p21Cip1 (Claassen and Hann, 2000). c-Myc also recruits histone acetylase complexes (Bouchard et al., 2001; Frank et al., 2001), unfolds the chromatin structure in somatic cells and enables under-privileged sites to undergo remodelling.

The four transcription factors participate in the maintenance of the pluripotent state, where Oct4, Sox2 and Klf4 constitute the core apparatus and c-Myc manipulates a wider scope of cellular functions. Although the genomic targets of

Timeline | Advancements in iPS cell technology since its inception




Figure 2. Timeline showing advancements in iPS cell technology since its inception. iPS, induced pluripotent stem.

each transcription factor act as jigsaw pieces to the pluripotency network puzzle, they do not necessarily reflect the molecular changes coupled to reprogramming *in vivo*. To acquire a mechanistic view of reprogramming, additional components that participate in the process have been unraveled.

Identification of additional factors and pathways involved in reprogramming

To peel away layers of complexity behind induced pluripotency, several directed genetic screens have been endeavoured. A handful of genes such as *Glis1*, *Tbx3*, and *Prmt5* were discovered to improve the original protocol of generating iPS cells (Han et al., 2010; Maekawa et al., 2011; Nagamatsu et al., 2011).

Transcription factors which competently act as substitutes for the prescribed set of reprogramming factors illuminate the role of each gene in the context of reprogramming. Inspection of functional redundancy among family members reveals that relatives of *Klf4*, *Sox2*, and *c-Myc* could successfully operate as substitutes, whereas *Oct1* and *Oct6* were unable to replace *Oct4* (Nakagawa et al., 2008). Subsequent findings denote the ability of *Nr5a2*, *Esrrb* and *Utf1* to replace *Oct4*, *Klf4*, and *c-Myc*, respectively (Zhao et al., 2008; Feng et al., 2009; Heng et al., 2010). In the absence of *Sox2*, *Prmt5* and *Nanog* function as substitutes (Ichida et al., 2009; Nagamatsu et al., 2011), with the latter attributed to its synergistic function with *Sox2* (Rodda et al., 2005).

Using an unbiased piggyBac-assisted approach, we show that *RAR γ* and *NR5A2* (*LRH-1*) co-operate to augment the transcriptional activity of *Oct4* and trigger rapid dedifferentiation (Wang et al., 2011b and unpublished data). Although implication of the retinoic acid pathway in the reprogramming process is surprising, it is not completely unexpected (Ben-Shushan et al., 1995; Barnea and Bergman, 2000). As the dedifferentiation process is distinct to the maintenance of ES cell pluripotency, this study may shed light from a new perspective on the molecular mechanisms behind reprogramming.

Aside from transcription factors, microRNAs have also been addressed (Judson et al., 2009; Liao et al., 2011; Subramanyam et al., 2011). Two independent studies reported that microRNAs alone could reprogram both mouse and human somatic cells (Anokye-Danso et al., 2011; Miyoshi et al., 2011). Extending this discovery, a new class of large intergenic non-coding RNAs (*lincRNAs*) was portrayed to be involved in pluripotency. Of 10 *lincRNAs* identified to be differentially expressed in iPS and ES cells, deregulation of *lincRNA-RoR* in human fibroblasts has been described to affect iPS cell formation (Loewer et al., 2010).

Chemicals that enhance reprogramming

The route to pluripotency is multi-faceted and complementing

chemical screens can illuminate potential approaches to improve the reprogramming process.

Transcription factor induced pluripotency occurs at sub-optimal frequencies of 0.01%–0.2% (reviewed by Hochedlinger and Plath, 2009). Forced re-expression of reprogramming factors in secondary fibroblasts resulted in 20% of cells displaying early pluripotency markers but a mere 1.2% of these cells re-activating their endogenous *Nanog* locus after 16 days (Mikkelsen et al., 2008). Amalgamating this to the knowledge that primitive cells which encompass fewer somatic epigenetic marks are more pliable to dedifferentiation and iPS cells which harbour incomplete erasure of silencing modifications were unable to contribute to the mouse germline (Takahashi and Yamanaka, 2006), it is tempting to speculate that overcoming the epigenetic barrier would enhance reprogramming.

To address this, a DNA methyltransferase inhibitor, AZA, was described to propel partially reprogrammed cells into pluripotency and improved the efficiency of producing iPS cell colonies by 4-fold (Huangfu et al., 2008a; Mikkelsen et al., 2008). Given that *c-Myc* regulates histone deacetylation and greatly improves reprogramming efficiencies, histone deacetylase inhibitors, such as valproic acid, trichostatin A, and suberoylanilide hydroxamic acid, have been proven to be efficacious in increasing the kinetics and efficiencies of generating iPS cells (Huangfu et al., 2008a, 2008b). Moreover, valproic acid ablates the need for *c-Myc* and *Klf4*, producing ES-like cells solely in the presence of *Oct4* and *Sox2*.

As reprogramming leads to the accumulation of reactive oxygen species, antioxidant vitamin C was described to increase the efficiency of generating iPS cells (Esteban et al., 2010). This is triggered by vitamin C-dependent H3K36me2/3 demethylation and the repression of *p53/p21* and *Ink4/Arf* loci (Wang et al., 2011a).

Besides the addition of chemicals, altering environmental conditions during reprogramming can also benefit the generation of iPS cells. In a natural setting, development of embryos occurs in physiologically hypoxic conditions. Recapitulating low oxygen concentrations during reprogramming experiments increases the efficiency of obtaining iPS cells (Yoshida et al., 2009). Furthermore, resultant female human iPS cells exhibit two activated copies of X chromosomes, indicating the attainment of ground state pluripotency (Lengner et al., 2010). Possible explanations behind this phenomenon include decreased accumulation of chromosomal abnormalities (Forsyth et al., 2006) and protection against spontaneous differentiation (Ezashi et al., 2005; Prasad et al., 2009).

Cellular processes associated with reprogramming

Although the search for genes and chemicals that enhance the creation of iPS cells has yielded a considerable amount of

information, other avenues of studying the dedifferentiation process have also provided us with much insight. Two complementary approaches were used to determine the importance of mesenchymal-to-epithelial transition (MET) during the reprogramming process (Li et al., 2010; Samavarchi-Tehrani et al., 2010). Molecular dissection of the process identified bone morphogenetic proteins (BMP) as a key mediator, leading to a later discovery that BMP can replace Klf4 in the reprogramming process, and its expression with Oct4 alone is sufficient to generate iPS cells (Chen et al., 2011). These findings were corroborated by two independent studies describing the essential roles of E-cadherin (Redmer et al., 2011) and the TGF β pathway (Ichida et al., 2009) in driving partially reprogrammed cells to pluripotency.

Secondary cells isolated from chimeras act as a homogeneous platform to study the mechanics behind induced pluripotency. Silencing p53 or p21, or over-expressing Lin28 in secondary B-cells improved reprogramming efficiencies in a cell division dependent manner (Hanna et al., 2009). This validated an initial finding that silencing p53 in primary fibroblasts improved reprogramming conditions (Zhao et al., 2008). In addition five studies also illustrated the role of DNA damage response and immortalization in reprogramming (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009a; Marión et al., 2009; Utikal et al., 2009).

The importance of cell division in generating iPS cells is disparate to the mechanics behind SCNT and cell fusion, insinuating that the current recipe of transcription factors is unable to replicate natural reprogramming events. Interestingly, delivery of Nanog into secondary B-cells increased the number of reprogrammed colonies, independent of cell division (Hanna et al., 2009). Nanog is known to play essential roles in reprogramming and cell fusion (Silva et al., 2006; Chambers et al., 2007; Yu et al., 2007; Silva et al., 2009), hence it is possible that it functions in a discrete role, providing a new dimension to the process.

Functional applications of iPS cells

The discovery of iPS cells was accompanied with the promise of personalized cell therapy and the creation of avenues for drug screening and disease modeling. Since the advent of this technology, several studies have been conducted to serve as proof-of-principle for future applications.

Foremost, it is important to demonstrate that biopsies retrieved from patients can be competently reprogrammed and recapitulate the disease when differentiated. To this end, dermal fibroblasts, primary hepatocytes, blood, and keratinocytes have been shown to be effectively reprogrammed (Aasen et al., 2008; Dimos et al., 2008; Giorgetti et al., 2009; Loh et al., 2009; Liu et al., 2010). Extending these findings, the first notion of disease modeling was established through the generation of iPS cells from patients with a series of hu-

man disorders (Park et al., 2008). This was further exemplified in amyotrophic lateral sclerosis where reprogrammed cells could effectively differentiate into motor neurons (Dimos et al., 2008), displaying its capacity to model the disease. A plethora of diseases have since been recapitulated, including familial hypercholesterolemia, X-linked adrenoleukodystrophy, dyskeratosis congenital, Hutchinson-Gilford Progeria syndrome, and Down's Syndrome (Rashid et al., 2010; Agarwal et al., 2010; Jang et al., 2011; Zhang et al., 2011; Shi et al., 2012).

iPS cells also act as a suitable platform to perform drug screening tests, as portrayed in Long QT syndrome type I (Moretti et al., 2010; Itzhaki et al., 2011). Cardiomyocytes differentiated from patient derived cells demonstrated the classical electrocardiographic aberration of a long QT interval and were susceptible to catecholamine-induced tachyarrhythmia, whereas the addition of β -adrenergic receptor blockers could rescue this phenotypic abnormality. Drug screening abilities of iPS cells have also been illustrated in the contexts of spinal muscular atrophy and familial dysautonomia ((Ebert et al., 2009; Lee et al., 2009).

The inception of iPS cell technology highlights the potential of cell therapy and has been addressed in an autologous mouse model displaying sickle cell anemia (Hanna et al., 2007). This was followed by the notion of human iPS cell therapy in the treatment of spinal cord injuries and Fanconi anemia (FA) (Raya et al., 2009; Nori et al., 2011). More recently, targeted gene correction in human iPS cells was demonstrated through the application of piggyBac transposons and zinc-finger nucleases (Yusa et al., 2011), surmounting potential silencing modifications of rescue cassettes delivered by viruses (Raya et al., 2009).

Although the use of iPS cells in the clinic is regarded attractively, there are several anomalies which have to be addressed. Cells derived from patients suffering from FA and Fragile X (FX) syndrome are not easily amenable (Raya et al., 2009; Urbach et al., 2010), where additional genetic modifications are necessary to produce FA iPS cells, and FX iPS cells do not recapitulate the disease phenotype. These bottlenecks impede disease modelling and amendments to the existing protocol have to be taken into consideration.

Current pitfalls in reprogramming

In addition to technical difficulties, there are several concerns about the authenticity of iPS cells, in relation to ES cells. Using available techniques, rigorous comparisons have been performed between ES cells and iPS cells. Comprehensive studies of phosphoproteomic and transcriptomic components revealed minute differences that were statistically disregarded (Phanstiel et al., 2011). However, epigenomic analysis at high resolution revealed subtle differences between human iPS cells and ES cells (Lister et al., 2011). Differentially methylated regions (DMRs) associated with CG islands

and genes were observed and these differences can be catalogued to represent persistent methylation patterns from the parental cell and *de novo* signatures specific to iPSCs. Additionally, aberrant silencing of the imprinted *Dlk1-Dio3* gene cluster on chromosome 12qF1 in mice has also been correlated to poor chimera contributions and low germline competence (Stadtfield et al., 2010). Overall, these studies point out that there are epigenetic discrepancies between iPSC cells and ES cells.

Given these differences, it is understandable that functional disparities, such as epigenetic memory, exist between iPSC cells and ES cells (Kim et al., 2010; Polo et al., 2010; Ohi et al., 2011). Blood-derived iPSC cells displayed higher competence in differentiating into blood cells than neural progenitor-derived iPSC cells, but at similar competence to nuclear-transfer-derived ESCs (Kim et al., 2010). However, differentiation of non-blood cells into blood prior to a second round of reprogramming markedly increases their blood forming capability, reiterating the notion of epigenetic footprints corresponding to the somatic state prior to reprogramming.

Another concern which has risen recently is the immunogenicity of autologous iPSC cells. Injection of allogenic ES cells or highly autologous iPSC cells into immune competent C57BL/6 mice elicited an immune response (Zhao et al., 2011). In contrast, autologous C57BL/6 ES cells were successfully implanted and generated teratomas efficiently. Reasons behind this phenomenon remain unclear but it is crucial that these observations are reproduced in independent studies before they can be generalized.

Given the differences between iPSC cells and ES cells, it is pivotal to refine our methods in reprogramming. Prolonged maintenance of iPSC cells has been suggested to erase sustained epigenetic marks (Polo et al., 2010); however continuous *in vitro* culture of these cells may incur genomic aberrations, as suggested by several independent groups (Gore et al., 2011; Hussein et al., 2011; Lister et al., 2011). Alternatively, the stoichiometry of the reprogramming factors has been suggested to affect the epigenetic status of the reprogrammed cells, strongly influencing their pluripotency (Carey et al., 2011).

Ground state or naïve pluripotent stem cells

To date, several stages of pluripotency have been recapitulated on a Petri dish (Fig. 3). ES cells derived from the inner cell mass of the mouse blastocyst (Evans and Kaufman, 1981) depict a naïve state of pluripotency and display germline competence when reintroduced into the mouse blastocyst. In culture, ES cells require LIF and BMP for maintenance. The addition of GSK3 β and MEK inhibitors (2i) shields these pluripotent cells from differentiation-inducing stimuli and select for a homogenous population of primitive cells, designated as ground state pluripotency (Ying et al., 2008).

Introduction of 2i to early mouse embryos does not impede blastocyst formation and results in high uniform expression of *Nanog* within the inner cell mass (Nichols et al., 2009). This proposes the presence of ground state pluripotency within the early mouse embryo, as denoted by the *Nanog*-expressing cells.

EpiSCs (EpiSCs) were established from late epiblast layers and represent a primed pluripotent state (Brons et al., 2007; Tesar et al., 2007). In contrast to ES cells, EpiSCs are maintained in fibroblast growth factor (FGF) and Activin. Grown as flat compact colonies, they are morphologically distinct from domed mouse ES cell colonies, and can rarely generate chimeras when injected into immune-compromised mice. EpiSCs can be converted into ES cells through the addition of LIF or the ectopic expression of *Klf2*, *Klf4*, or *Nr5a2* and the addition of 2i and LIF (Bao et al., 2009; Guo et al., 2009; Guo and Smith, 2010).

Human ES cells have been successfully isolated from human blastocysts (Thomson et al., 1998). Unlike mouse ES cells, the human ES cells require FGF and/or Activin for sustenance and the presence of LIF is insufficient to maintain them in an undifferentiated state. These pieces of evidence suggest that human ES cells resemble EpiSCs to a higher degree than their mouse counterparts (Tesar et al., 2007), indicating the existence of an unexplored naïve human pluripotent state. This notion is strengthened by the recent finding that *Nanog*-expressing cells within the human embryo do not respond to the inhibition of FGF and extracellular signal-regulated kinases (ERK) signals (Kuijk et al., 2012; Roode et al., 2012).

Given that conventional human iPSC cells display a close relationship to human ES cells, the establishment of a stable primitive state may overcome the bottlenecks experienced by traditional human iPSC cells. To address this, several studies have attempted to isolate immature human iPSC cells. These strategies revolve around the ectopic constitutive expression of expanded sets of transcription factors and the addition of a spectrum of chemicals (Li et al., 2009b; Buecker et al., 2010; Hanna et al., 2010). Resultant cells resemble ES cells morphologically and display X-reactivation in female cells.

More recently, we have demonstrated that a cocktail of RAR γ , *Nr5a2* and the conventional set of reprogramming factors, can create naïve human pluripotent cells (Wang et al., 2011b). Coined as Sanger human iPSC (SH-iPSC) cells, these cells are stable over 50 passages, display dependency on the JAK/Stat pathway and generate teratomas when injected into immune-compromised mice. Using female cells as a starting material, SH-iPSC cells exhibit two active X-chromosomes. Interestingly, exposure to FGF and Activin triggered their conversion to human ES-like cells, resembling the conversion of mouse ES cells to EpiSCs in similar conditions. This affirms the existence of a stable naïve state in human induced pluripotency and its competence to be maintained in culture.




Figure 3. Comparison between different pluripotent states in the mouse and human.

The discovery of this primitive state in human cells has immense implications. FGF-dependent human ES cells and iPS cells are technically difficult to maintain in culture. Susceptible to harsh dissociation, these cells are unable to survive devoid of cell–cell interaction and exhibit genetic instability (Brimble et al., 2004; Buzzard et al., 2004; Lefort et al., 2008; Spits et al., 2008; Mayshar et al., 2010; Ams et al., 2011). In contrast, naïve human iPS cells do not display these properties and can be manipulated with ease. Resistant to tougher handling techniques, these cells are possibly more amenable to homologous recombination, creating a huge potential for genetic modification and correction. Naïve human iPS cells are also genetically and epigenetically stable, overcoming hurdles for its prospective use in the clinic. Despite these advantages, current protocols to derive naïve human iPS cells are not optimal. Further development is necessary to improve reprogramming efficiencies to levels comparable to or better than the generation of conventional FGF-dependent iPS cells. Nevertheless, since the inception of transcription factor induced pluripotency, the wealth of knowledge has amassed exponentially and continuation on this journey will inch us towards the translation of this technology to the bedside.

ABBREVIATIONS

EC cells, embryonic carcinoma cells; ES cells, embryonic stem cells; EpiSCs, Epiblast stem cells; ERK, extracellular signal-regulated kinases; FGF, fibroblast growth factor; iPS cells, induced pluripotent stem cells; LIF, leukemia inhibitory factor; SCNT, somatic cell nuclear transfer; 2i, two inhibitors

REFERENCES

- Aasen, T., Raya, A., Barrero, M.J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilić, J., Pekarik, V., Tiscornia, G., et al. (2008). Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. *Nat Biotechnol* 26, 1276–1284.
- Agarwal, S., Loh, Y.H., McLoughlin, E.M., Huang, J., Park, I.H., Miller, J.D., Huo, H., Okuka, M., Dos Reis, R.M., Loewer, S., et al. (2010). Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. *Nature* 464, 292–296.
- Ams, K., Andrews, P.W., Anyfantis, G., Armstrong, L., Avery, S., Baharvand, H., Baker, J., Baker, D., Munoz, M.B., Beil, S., et al., and the International Stem Cell Initiative. (2011). Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. *Nat Biotechnol* 29, 1132–1144.
- Anokye-Danso, F., Trivedi, C.M., Juhr, D., Gupta, M., Cui, Z., Tian, Y., Zhang, Y., Yang, W., Gruber, P.J., Epstein, J.A., et al. (2011). Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell* 8, 376–388.
- Aoi, T., Yae, K., Nakagawa, M., Ichisaka, T., Okita, K., Takahashi, K., Chiba, T., and Yamanaka, S. (2008). Generation of pluripotent stem cells from adult mouse liver and stomach cells. *Science* 321, 699–702.
- Avilion, A.A., Nicolis, S.K., Pevny, L.H., Perez, L., Vivian, N., and Lovell-Badge, R. (2003). Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* 17, 126–140.
- Bao, S., Tang, F., Li, X., Hayashi, K., Gillich, A., Lao, K., and Surani, M.A. (2009). Epigenetic reversion of post-implantation epiblast to pluripotent embryonic stem cells. *Nature* 461, 1292–1295.
- Barnea, E., and Bergman, Y. (2000). Synergy of SF1 and RAR in activation of Oct-3/4 promoter. *J Biol Chem* 275, 6608–6619.
- Becker, M., Becker, A., Miyara, F., Han, Z., Kihara, M., Brown, D.T., Hager, G.L., Latham, K., Adashi, E.Y., and Misteli, T. (2005). Differential in vivo binding dynamics of somatic and oocyte-specific linker histones in oocytes and during ES cell nuclear transfer. *Mol Biol Cell* 16, 3887–3895.
- Ben-Shushan, E., Sharir, H., Pikarsky, E., and Bergman, Y. (1995). A dynamic balance between ARP-1/COUP-TFII, EAR-3/COUP-TFI, and retinoic acid receptor:retinoid X receptor heterodimers regulates Oct-3/4 expression in embryonal carcinoma cells. *Mol Cell Biol* 15, 1034–1048.
- Blau, H.M., Chiu, C.P., and Webster, C. (1983). Cytoplasmic activation of human nuclear genes in stable heterocaryons. *Cell* 32, 1171–1180.
- Bouchard, C., Dittrich, O., Kiermaier, A., Dohmann, K., Menkel, A., Eilers, M., and Lüscher, B. (2001). Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. *Genes Dev* 15, 2042–2047.
- Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G., Kumar, R.M., Murray, H.L., Jenner, R.G., et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 122, 947–956.
- Briggs, R., and King, T.J. (1952). Transplantation of Living Nuclei From Blastula Cells into Enucleated Frogs' Eggs. *Proc Natl Acad Sci U S A* 38, 455–463.
- Brimble, S.N., Zeng, X., Weiler, D.A., Luo, Y., Liu, Y., Lyons, I.G., Freed, W.J., Robins, A.J., Rao, M.S., and Schulz, T.C. (2004). Karyotypic stability, genotyping, differentiation, feeder-free maintenance, and gene expression sampling in three human embryonic stem cell lines derived prior to August 9, 2001. *Stem Cells Devel* 13, 585–597.
- Brons, I.G., Smithers, L.E., Trotter, M.W., Rugg-Gunn, P., Sun, B., Chuva de Sousa Lopes, S.M., Howlett, S.K., Clarkson, A., Ahrlund-Richter, L., Pedersen, R.A., et al. (2007). Derivation of pluripotent epiblast stem cells from mammalian embryos. *Nature* 448, 191–195.
- Buecker, C., Chen, H.H., Polo, J.M., Daheron, L., Bu, L., Barakat, T.S., Okwieka, P., Porter, A., Gribnau, J., Hochedlinger, K., et al. (2010). A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells. *Cell Stem Cell* 6, 535–546.
- Buzzard, J.J., Gough, N.M., Crook, J.M., and Colman, A. (2004). Karyotype of human ES cells during extended culture. *Nat Biotechnol* 22, 381–382, author reply 382.
- Byrne, J.A., Simonsson, S., Western, P.S., and Gurdon, J.B. (2003). Nuclei of adult mammalian somatic cells are directly reprogrammed to oct-4 stem cell gene expression by amphibian oocytes. *Curr Biol* 13, 1206–1213.

- Carey, B.W., Markoulaki, S., Hanna, J., Saha, K., Gao, Q., Mitalipova, M., and Jaenisch, R. (2009). Reprogramming of murine and human somatic cells using a single polycistronic vector. *Proc Natl Acad Sci U S A* 106, 157–162.
- Carey, B.W., Markoulaki, S., Hanna, J.H., Faddah, D.A., Buganim, Y., Kim, J., Ganz, K., Steine, E.J., Cassady, J.P., Creighton, M.P., et al. (2011). Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. *Cell Stem Cell* 9, 588–598.
- Cartwright, P., McLean, C., Sheppard, A., Rivett, D., Jones, K., and Dalton, S. (2005). LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. *Development* 132, 885–896.
- Chambers, I., Silva, J., Colby, D., Nichols, J., Nijmeijer, B., Robertson, M., Vrana, J., Jones, K., Grotewold, L., and Smith, A. (2007). Nanog safeguards pluripotency and mediates germline development. *Nature* 450, 1230–1234.
- Chen, J., Liu, J., Yang, J., Chen, Y., Chen, J., Ni, S., Song, H., Zeng, L., Ding, K., and Pei, D. (2011). BMPs functionally replace Klf4 and support efficient reprogramming of mouse fibroblasts by Oct4 alone. *Cell Res* 21, 205–212.
- Chen, X., Xu, H., Yuan, P., Fang, F., Huss, M., Vega, V.B., Wong, E., Orlov, Y.L., Zhang, W., Jiang, J., et al. (2008). Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. *Cell* 133, 1106–1117.
- Chew, J.L., Loh, Y.H., Zhang, W., Chen, X., Tam, W.L., Yeap, L.S., Li, P., Ang, Y.S., Lim, B., Robson, P., et al. (2005). Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. *Mol Cell Biol* 25, 6031–6046.
- Chickarmane, V., Enver, T., and Peterson, C. (2009). Computational modeling of the hematopoietic erythroid-myeloid switch reveals insights into cooperativity, priming, and irreversibility. *PLoS Comput Biol* 5, e1000268.
- Chiu, C.P., and Blau, H.M. (1985). 5-Azacytidine permits gene activation in a previously noninducible cell type. *Cell* 40, 417–424.
- Claassen, G.F., and Hann, S.R. (2000). A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. *Proc Natl Acad Sci U S A* 97, 9498–9503.
- Cowan, C.A., Atienza, J., Melton, D.A., and Eggan, K. (2005). Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. *Science* 309, 1369–1373.
- Dejosez, M., Krumenacker, J.S., Zitur, L.J., Passeri, M., Chu, L.F., Songyang, Z., Thomson, J.A., and Zwaka, T.P. (2008). Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells. *Cell* 133, 1162–1174.
- DiBerardino, M.A., and Hoffner, N.J. (1983). Gene reactivation in erythrocytes: nuclear transplantation in oocytes and eggs of *Rana*. *Science* 219, 862–864.
- Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., Chung, W., Croft, G.F., Saphier, G., Leibel, R., Golland, R., et al. (2008). Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 321, 1218–1221.
- Do, J.T., and Scholer, H.R. (2010). Cell fusion-induced reprogramming. *Meth Mol Biol* 636, 179–190.
- Driesch, H. (1894). Analytische theorie der organischen entwicklung (Leipzig, W. Engelmann).
- Ebert, A.D., Yu, J., Rose, F.F. Jr, Mattis, V.B., Lorson, C.L., Thomson, J.A., and Svendsen, C.N. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature* 457, 277–280.
- Eilken, H.M., Nishikawa, S., and Schroeder, T. (2009). Continuous single-cell imaging of blood generation from haemogenic endothelium. *Nature* 457, 896–900.
- Esteban, M.A., Wang, T., Qin, B., Yang, J., Qin, D., Cai, J., Li, W., Weng, Z., Chen, J., Ni, S., et al. (2010). Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. *Cell Stem Cell* 6, 71–79.
- Esteban, M.A., Xu, J., Yang, J., Peng, M., Qin, D., Li, W., Jiang, Z., Chen, J., Deng, K., Zhong, M., et al. (2009). Generation of induced pluripotent stem cell lines from Tibetan miniature pig. *J Biol Chem* 284, 17634–17640.
- Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292, 154–156.
- Ezashi, T., Das, P., and Roberts, R.M. (2005). Low O₂ tensions and the prevention of differentiation of hES cells. *Proc Natl Acad Sci U S A* 102, 4783–4788.
- Feng, B., Jiang, J., Kraus, P., Ng, J.H., Heng, J.C., Chan, Y.S., Yaw, L.P., Zhang, W., Loh, Y.H., Han, J., et al. (2009). Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. *Nat Cell Biol* 11, 197–203.
- Flasza, M., Shering, A.F., Smith, K., Andrews, P.W., Talley, P., and Johnson, P.A. (2003). Reprogramming in inter-species embryonal carcinoma-somatic cell hybrids induces expression of pluripotency and differentiation markers. *Cloning Stem Cells* 5, 339–354.
- Forsyth, N.R., Musio, A., Vezzoni, P., Simpson, A.H., Noble, B.S., and McWhir, J. (2006). Physiologic oxygen enhances human embryonic stem cell clonal recovery and reduces chromosomal abnormalities. *Cloning Stem Cells* 8, 16–23.
- Frank, S.R., Schroeder, M., Fernandez, P., Taubert, S., and Amati, B. (2001). Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. *Genes Dev* 15, 2069–2082.
- Freberg, C.T., Dahl, J.A., Timoskainen, S., and Collas, P. (2007). Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. *Mol Biol Cell* 18, 1543–1553.
- French, A.J., Adams, C.A., Anderson, L.S., Kitchen, J.R., Hughes, M.R., and Wood, S.H. (2008). Development of human cloned blastocysts following somatic cell nuclear transfer with adult fibroblasts. *Stem Cells* 26, 485–493.
- Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., and Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* 85, 348–362.
- Gao, S., Chung, Y.G., Parseghian, M.H., King, G.J., Adashi, E.Y., and Latham, K.E. (2004). Rapid H1 linker histone transitions following fertilization or somatic cell nuclear transfer: evidence for a uniform developmental program in mice. *Dev Biol* 266, 62–75.
- Giorgetti, A., Montserrat, N., Aasen, T., Gonzalez, F., Rodríguez-Pizà, I., Vassena, R., Raya, A., Boué, S., Barrero, M.J., Corbella, B.A., et al. (2009). Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. *Cell Stem Cell* 5,

- 353–357.
- Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., Giorgetti, A., Israel, M.A., Kiskinis, E., et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. *Nature* 471, 63–67.
- Guo, G., and Smith, A. (2010). A genome-wide screen in EpiSCs identifies Nr5a nuclear receptors as potent inducers of ground state pluripotency. *Development* 137, 3185–3192.
- Guo, G., Yang, J., Nichols, J., Hall, J.S., Eyres, I., Mansfield, W., and Smith, A. (2009). Klf4 reverts developmentally programmed restriction of ground state pluripotency. *Development* 136, 1063–1069.
- Gurdon, J.B. (1962a). Adult frogs derived from the nuclei of single somatic cells. *Dev Biol* 4, 256–273.
- Gurdon, J.B. (1962b). The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. *J Embryol Exp Morphol* 10, 622–640.
- Gurdon, J.B., Brennan, S., Fairman, S., and Mohun, T.J. (1984). Transcription of muscle-specific actin genes in early *Xenopus* development: nuclear transplantation and cell dissociation. *Cell* 38, 691–700.
- Gurdon, J.B., Elsdale, T.R., and Fischberg, M. (1958). Sexually mature individuals of *Xenopus laevis* from the transplantation of single somatic nuclei. *Nature* 182, 64–65.
- Gurdon, J.B., Laskey, R.A., and Reeves, O.R. (1975). The developmental capacity of nuclei transplanted from keratinized skin cells of adult frogs. *J Embryol Exp Morphol* 34, 93–112.
- Hall, J., Guo, G., Wray, J., Eyres, I., Nichols, J., Grotewold, L., Morfopoulou, S., Humphreys, P., Mansfield, W., Walker, R., et al. (2009). Oct4 and LIF/Stat3 additively induce Krüppel factors to sustain embryonic stem cell self-renewal. *Cell Stem Cell* 5, 597–609.
- Hall, V.J., Compton, D., Stojkovic, P., Nesbitt, M., Herbert, M., Murdoch, A., and Stojkovic, M. (2007). Developmental competence of human in vitro aged oocytes as host cells for nuclear transfer. *Hum Reprod* 22, 52–62.
- Han, J., Yuan, P., Yang, H., Zhang, J., Soh, B.S., Li, P., Lim, S.L., Cao, S., Tay, J., Orlov, Y.L., et al. (2010). Tbx3 improves the germ-line competency of induced pluripotent stem cells. *Nature* 463, 1096–1100.
- Hanna, J., Cheng, A.W., Saha, K., Kim, J., Lengner, C.J., Soldner, F., Cassady, J.P., Muffat, J., Carey, B.W., and Jaenisch, R. (2010). Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. *Proc Natl Acad Sci U S A* 107, 9222–9227.
- Hanna, J., Markoulaki, S., Schorderet, P., Carey, B.W., Beard, C., Wernig, M., Creyghton, M.P., Steine, E.J., Cassady, J.P., Foreman, R., et al. (2008). Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. *Cell* 133, 250–264.
- Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C.J., Creyghton, M.P., van Oudenaarden, A., and Jaenisch, R. (2009). Direct cell reprogramming is a stochastic process amenable to acceleration. *Nature* 462, 595–601.
- Hanna, J., Wernig, M., Markoulaki, S., Sun, C.W., Meissner, A., Cassady, J.P., Beard, C., Brambrink, T., Wu, L.C., Townes, T.M., et al. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. *Science* 318, 1920–1923.
- Hansis, C., Barreto, G., Maltry, N., and Niehrs, C. (2004). Nuclear reprogramming of human somatic cells by *xenopus* egg extract requires BRG1. *Curr Biol* 14, 1475–1480.
- Harris, H. (1965). Behaviour of differentiated nuclei in heterokaryons of animal cells from different species. *Nature* 206, 583–588.
- Harris, H., Watkins, J.F., Ford, C.E., and Schoeffl, G.I. (1966). Artificial heterokaryons of animal cells from different species. *J Cell Sci* 1, 1–30.
- Heng, J.C., Feng, B., Han, J., Jiang, J., Kraus, P., Ng, J.H., Orlov, Y.L., Huss, M., Yang, L., Lufkin, T., et al. (2010). The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. *Cell Stem Cell* 6, 167–174.
- Hochedlinger, K., and Plath, K. (2009). Epigenetic reprogramming and induced pluripotency. *Development* 136, 509–523.
- Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., and Yamanaka, S. (2009). Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. *Nature* 460, 1132–1135.
- Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and Melton, D.A. (2008a). Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol* 26, 795–797.
- Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W., and Melton, D.A. (2008b). Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. *Nat Biotechnol* 26, 1269–1275.
- Hussein, S.M., Batada, N.N., Vuoristo, S., Ching, R.W., Autio, R., Närvä, E., Ng, S., Sourour, M., Hämäläinen, R., Olsson, C., et al. (2011). Copy number variation and selection during reprogramming to pluripotency. *Nature* 471, 58–62.
- Ichida, J.K., Blanchard, J., Lam, K., Son, E.Y., Chung, J.E., Egli, D., Loh, K.M., Carter, A.C., Di Giorgio, F.P., Koszka, K., et al. (2009). A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. *Cell Stem Cell* 5, 491–503.
- Ieda, M., Fu, J.D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B.G., and Srivastava, D. (2010). Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell* 142, 375–386.
- Inoue, A., and Zhang, Y. (2011). Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. *Science* 334, 194.
- Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstem, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011). Modelling the long QT syndrome with induced pluripotent stem cells. *Nature* 471, 225–229.
- Iwasaki, H., Mizuno, S., Arinobu, Y., Ozawa, H., Mori, Y., Shigematsu, H., Takatsu, K., Tenen, D.G., and Akashi, K. (2006). The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. *Genes Dev* 20, 3010–3021.
- Jang, J., Kang, H.C., Kim, H.S., Kim, J.Y., Huh, Y.J., Kim, D.S., Yoo, J.E., Lee, J.A., Lim, B., Lee, J., et al. (2011). Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. *Ann Neurol* 70, 402–409.
- Jiang, J., Chan, Y.S., Loh, Y.H., Cai, J., Tong, G.Q., Lim, C.A., Robson, P., Zhong, S., and Ng, H.H. (2008). A core Klf circuitry

- regulates self-renewal of embryonic stem cells. *Nat Cell Biol* 10, 353–360.
- Judson, R.L., Babiarz, J.E., Venere, M., and Blueloch, R. (2009). Embryonic stem cell-specific microRNAs promote induced pluripotency. *Nat Biotechnol* 27, 459–461.
- Jullien, J., Astrand, C., Halley-Stott, R.P., Garrett, N., and Gurdon, J.B. (2010). Characterization of somatic cell nuclear reprogramming by oocytes in which a linker histone is required for pluripotency gene reactivation. *Proc Natl Acad Sci U S A* 107, 5483–5488.
- Kajimura, S., Seale, P., Kubota, K., Lunsford, E., Frangioni, J.V., Gygi, S.P., and Spiegelman, B.M. (2009). Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. *Nature* 460, 1154–1158.
- Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A., Wahl, G.M., and Izpisua Belmonte, J.C. (2009). Linking the p53 tumour suppressor pathway to somatic cell reprogramming. *Nature* 460, 1140–1144.
- Kim, D., Kim, C.H., Moon, J.I., Chung, Y.G., Chang, M.Y., Han, B.S., Ko, S., Yang, E., Cha, K.Y., Lanza, R., et al. (2009a). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. *Cell Stem Cell* 4, 472–476.
- Kim, J., Chu, J., Shen, X., Wang, J., and Orkin, S.H. (2008). An extended transcriptional network for pluripotency of embryonic stem cells. *Cell* 132, 1049–1061.
- Kim, J.B., Greber, B., Araúzo-Bravo, M.J., Meyer, J., Park, K.I., Zaehres, H., and Schöler, H.R. (2009b). Direct reprogramming of human neural stem cells by OCT4. *Nature* 461, 649–653.
- Kim, J.B., Sebastiano, V., Wu, G., Araúzo-Bravo, M.J., Sasse, P., Gentile, L., Ko, K., Ruau, D., Ehrlich, M., van den Boom, D., et al. (2009c). Oct4-induced pluripotency in adult neural stem cells. *Cell* 136, 411–419.
- Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M.J., Ji, H., Ehrlich, L.I., et al. (2010). Epigenetic memory in induced pluripotent stem cells. *Nature* 467, 285–290.
- King, T.J., and Briggs, R. (1955). Changes in the Nuclei of Differentiating Gastrula Cells, as Demonstrated by Nuclear Transplantation. *Proc Natl Acad Sci U S A* 41, 321–325.
- Klein, G. (1983). Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. *Cell* 32, 311–315.
- Kopp, J.L., Ormsbee, B.D., Desler, M., and Rizzino, A. (2008). Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. *Stem Cells* 26, 903–911.
- Kuijk, E.W., van Tol, L.T., Van de Velde, H., Wubbolts, R., Welling, M., Geijsen, N., and Roelen, B.A. (2012). The roles of FGF and MAP kinase signaling in the segregation of the epiblast and hypoblast cell lineages in bovine and human embryos. *Development* 139, 871–882.
- Kulesa, H., Frampton, J., and Graf, T. (1995). GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblats, and erythroblats. *Genes Dev* 9, 1250–1262.
- Laiosa, C.V., Stadtfeld, M., Xie, H., de Andres-Aguayo, L., and Graf, T. (2006). Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factors. *Immunity* 25, 731–744.
- Laskey, R.A., and Gurdon, J.B. (1970). Genetic content of adult somatic cells tested by nuclear transplantation from cultured cells. *Nature* 228, 1332–1334.
- Lee, G., Papapetrou, E.P., Kim, H., Chambers, S.M., Tomishima, M.J., Fasano, C.A., Ganat, Y.M., Menon, J., Shimizu, F., Viale, A., et al. (2009). Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature* 461, 402–406.
- Lefort, N., Feyeux, M., Bas, C., Féraud, O., Bennaceur-Griscelli, A., Tachdjian, G., Peschanski, M., and Perrier, A.L. (2008). Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. *Nat Biotechnol* 26, 1364–1366.
- Lengner, C.J., Gimelbrant, A.A., Erwin, J.A., Cheng, A.W., Guenther, M.G., Welstead, G.G., Alagappan, R., Frampton, G.M., Xu, P., Muffat, J., et al. (2010). Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. *Cell* 141, 872–883.
- Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., Blasco, M.A., and Serrano, M. (2009a). The Ink4/Arf locus is a barrier for iPS cell reprogramming. *Nature* 460, 1136–1139.
- Li, R., Liang, J., Ni, S., Zhou, T., Qing, X., Li, H., He, W., Chen, J., Li, F., Zhuang, Q., et al. (2010). A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. *Cell Stem Cell* 7, 51–63.
- Li, W., Wei, W., Zhu, S., Zhu, J., Shi, Y., Lin, T., Hao, E., Hayek, A., Deng, H., and Ding, S. (2009b). Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. *Cell Stem Cell* 4, 16–19.
- Liao, B., Bao, X., Liu, L., Feng, S., Zovoilis, A., Liu, W., Xue, Y., Cai, J., Guo, X., Qin, B., et al. (2011). MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. *J Biol Chem* 286, 17359–17364.
- Liao, J., Cui, C., Chen, S., Ren, J., Chen, J., Gao, Y., Li, H., Jia, N., Cheng, L., Xiao, H., et al. (2009). Generation of induced pluripotent stem cell lines from adult rat cells. *Cell Stem Cell* 4, 11–15.
- Lister, R., Pelizzola, M., Kida, Y.S., Hawkins, R.D., Nery, J.R., Hon, G., Antosiewicz-Bourget, J., O'Malley, R., Castanon, R., Klugman, S., et al. (2011). Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. *Nature* 471, 68–73.
- Liu, H., Ye, Z., Kim, Y., Sharkis, S., and Jang, Y.Y. (2010). Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. *Hepatology* 51, 1810–1819.
- Liu, H., Zhu, F., Yong, J., Zhang, P., Hou, P., Li, H., Jiang, W., Cai, J., Liu, M., Cui, K., et al. (2008). Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. *Cell Stem Cell* 3, 587–590.
- Loewer, S., Cabili, M.N., Guttman, M., Loh, Y.H., Thomas, K., Park, I.H., Garber, M., Curran, M., Onder, T., Agarwal, S., et al. (2010). Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. *Nat Genet* 42, 1113–1117.
- Loh, Y.H., Agarwal, S., Park, I.H., Urbach, A., Huo, H., Heffner, G.C., Kim, K., Miller, J.D., Ng, K., and Daley, G.Q. (2009). Generation of induced pluripotent stem cells from human blood. *Blood* 113, 5476–5479.
- Loh, Y.H., Wu, Q., Chew, J.L., Vega, V.B., Zhang, W., Chen, X., Bourque, G., George, J., Leong, B., Liu, J., et al. (2006). The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nat Genet* 38, 431–440.
- Maekawa, M., Yamaguchi, K., Nakamura, T., Shibukawa, R., Ko-

- danaka, I., Ichisaka, T., Kawamura, Y., Mochizuki, H., Goshima, N., and Yamanaka, S. (2011). Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. *Nature* 474, 225–229.
- Maherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld, M., Yachechko, R., Tchieu, J., Jaenisch, R., et al. (2007). Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. *Cell Stem Cell* 1, 55–70.
- Maki, N., Suetsugu-Maki, R., Sano, S., Nakamura, K., Nishimura, O., Tarui, H., Del Rio-Tsonis, K., Ohsumi, K., Agata, K., and Tsonis, P.A. (2010). Oocyte-type linker histone B4 is required for trans-differentiation of somatic cells in vivo. *FASEB J* 24, 3462–3467.
- Marión, R.M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., and Blasco, M.A. (2009). A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. *Nature* 460, 1149–1153.
- Masui, S., Nakatake, Y., Toyooka, Y., Shimosato, D., Yagi, R., Takahashi, K., Okochi, H., Okuda, A., Matoba, R., Sharov, A.A., et al. (2007). Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. *Nat Cell Biol* 9, 625–635.
- Mayshar, Y., Ben-David, U., Lavon, N., Biancotti, J.C., Yakir, B., Clark, A.T., Plath, K., Lowry, W.E., and Benvenisty, N. (2010). Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. *Cell Stem Cell* 7, 521–531.
- McGrath, J., and Solter, D. (1983). Nuclear transplantation in the mouse embryo by microsurgery and cell fusion. *Science* 1300–1302.
- Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., Bernstein, B.E., Jaenisch, R., Lander, E.S., and Meissner, A. (2008). Dissecting direct reprogramming through integrative genomic analysis. *Nature* 454, 49–55.
- Miyoshi, N., Ishii, H., Nagano, H., Haraguchi, N., Dewi, D.L., Kano, Y., Nishikawa, S., Tanemura, M., Mimori, K., Tanaka, F., et al. (2011). Reprogramming of mouse and human cells to pluripotency using mature microRNAs. *Cell Stem Cell* 8, 633–638.
- Moretti, A., Bellin, M., Welling, A., Jung, C.B., Lam, J.T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010). Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *N Engl J Med* 363, 1397–1409.
- Nagamatsu, G., Kosaka, T., Kawasumi, M., Kinoshita, T., Takubo, K., Akiyama, H., Sudo, T., Kobayashi, T., Oya, M., and Suda, T. (2011). A germ cell-specific gene, Prmt5, works in somatic cell reprogramming. *J Biol Chem* 286, 10641–10648.
- Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochizuki, Y., Takizawa, N., and Yamanaka, S. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat Biotechnol* 26, 101–106.
- Nichols, J., Silva, J., Roode, M., and Smith, A. (2009). Suppression of Erk signalling promotes ground state pluripotency in the mouse embryo. *Development* 136, 3215–3222.
- Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Schöler, H., and Smith, A. (1998). Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* 95, 379–391.
- Niwa, H., Miyazaki, J., and Smith, A.G. (2000). Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat Genet* 24, 372–376.
- Noggle, S., Fung, H.L., Gore, A., Martinez, H., Satriani, K.C., Prosser, R., Oum, K., Paull, D., Druckenmiller, S., Freeby, M., et al. (2011). Human oocytes reprogram somatic cells to a pluripotent state. *Nature* 478, 70–75.
- Nori, S., Okada, Y., Yasuda, A., Tsuji, O., Takahashi, Y., Kobayashi, Y., Fujiyoshi, K., Koike, M., Uchiyama, Y., Ikeda, E., et al. (2011). Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. *Proc Natl Acad Sci U S A* 108, 16825–16830.
- Ohi, Y., Qin, H., Hong, C., Blouin, L., Polo, J.M., Guo, T., Qi, Z., Downey, S.L., Manos, P.D., Rossi, D.J., et al. (2011). Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. *Nat Cell Biol* 13, 541–549.
- Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. *Nature* 448, 313–317.
- Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. *Science* 322, 949–953.
- Pander, C.H. (1817). Beiträge zur Entwicklungsgeschichte des Hühnchens im Eye (Wurzburg).
- Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M.W., Cowan, C., Hochedlinger, K., and Daley, G.Q. (2008). Disease-specific induced pluripotent stem cells. *Cell* 134, 877–886.
- Pavlat, G.K., and Blau, H.M. (1986). Expression of muscle genes in heterokaryons depends on gene dosage. *J Cell Biol* 102, 124–130.
- Pereira, C.F., Terranova, R., Ryan, N.K., Santos, J., Morris, K.J., Cui, W., Merkenschlager, M., and Fisher, A.G. (2008). Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2. *PLoS Genet* 4, e1000170.
- Phanstiel, D.H., Brumbaugh, J., Wenger, C.D., Tian, S., Probasco, M.D., Bailey, D.J., Swaney, D.L., Tervo, M.A., Bolin, J.M., Ruotti, V., et al. (2011). Proteomic and phosphoproteomic comparison of human ES and iPS cells. *Nat Methods* 8, 821–827.
- Polo, J.M., Liu, S., Figueroa, M.E., Kulalert, W., Eminli, S., Tan, K.Y., Apostolou, E., Stadtfeld, M., Li, Y., Shioda, T., et al. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nat Biotechnol* 28, 848–855.
- Prasad, S.M., Czepiel, M., Cetinkaya, C., Smigielska, K., Weli, S.C., Lysdahl, H., Gabrielsen, A., Petersen, K., Ehlers, N., Fink, T., et al. (2009). Continuous hypoxic culturing maintains activation of Notch and allows long-term propagation of human embryonic stem cells without spontaneous differentiation. *Cell Prolif* 42, 63–74.
- Rahl, P.B., Lin, C.Y., Seila, A.C., Flynn, R.A., McQuine, S., Burge, C.B., Sharp, P.A., and Young, R.A. (2010). c-Myc regulates transcriptional pause release. *Cell* 141, 432–445.
- Rashid, S.T., Corbinea, S., Hannan, N., Marciniak, S.J., Miranda, E., Alexander, G., Huang-Doran, I., Griffin, J., Ahrlund-Richter, L., Skepper, J., et al. (2010). Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. *J Clin Invest* 120, 3127–3136.
- Raya, A., Rodríguez-Pizà, I., Guenechea, G., Vassena, R., Navarro,

- S., Barrero, M.J., Consiglio, A., Castellà, M., Ríó, P., Sleep, E., et al. (2009). Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. *Nature* 460, 53–59.
- Redmer, T., Diecke, S., Grigoryan, T., Quiroga-Negreira, A., Birchmeier, W., and Besser, D. (2011). E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. *EMBO Rep* 12, 720–726.
- Rodda, D.J., Chew, J.L., Lim, L.H., Loh, Y.H., Wang, B., Ng, H.H., and Robson, P. (2005). Transcriptional regulation of nanog by OCT4 and SOX2. *J Biol Chem* 280, 24731–24737.
- Roode, M., Blair, K., Snell, P., Elder, K., Marchant, S., Smith, A., and Nichols, J. (2012). Human hypoblast formation is not dependent on FGF signalling. *Dev Biol* 361, 358–363.
- Roux, W. (1888). *Beitrage zur Entwicklungsmechanik des Embryo*. *Virchows Arch Pathol Anat Physiol Klin Med* 144, 113–153.
- Rowland, B.D., Bernards, R., and Peeper, D.S. (2005). The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. *Nat Cell Biol* 7, 1074–1082.
- Samavarchi-Tehrani, P., Golipour, A., David, L., Sung, H.K., Beyer, T.A., Datti, A., Woltjen, K., Nagy, A., and Wrana, J.L. (2010). Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. *Cell Stem Cell* 7, 64–77.
- Shi, Y., Do, J.T., Despots, C., Hahm, H.S., Schöler, H.R., and Ding, S. (2008). A combined chemical and genetic approach for the generation of induced pluripotent stem cells. *Cell Stem Cell* 2, 525–528.
- Shi, Y., Kirwan, P., Smith, J., Maclean, G., Orkin, S.H., and Livesey, F.J. (2012). A human stem cell model of early Alzheimer's disease pathology in Down Syndrome. *Sci Transl Med* 4, 124ra29.
- Silva, J., Chambers, I., Pollard, S., and Smith, A. (2006). Nanog promotes transfer of pluripotency after cell fusion. *Nature* 441, 997–1001.
- Silva, J., Nichols, J., Theunissen, T.W., Guo, G., van Oosten, A.L., Barrandon, O., Wray, J., Yamanaka, S., Chambers, I., and Smith, A. (2009). Nanog is the gateway to the pluripotent ground state. *Cell* 138, 722–737.
- Sommer, C.A., Stadtfeld, M., Murphy, G.J., Hochedlinger, K., Kotton, D.N., and Mostoslavsky, G. (2009). Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. *Stem Cells* 27, 543–549.
- Spemann, H. (1928). Die Entwicklung seitlicher und dorso-ventraler Keimhalften bei verzögerter Kernversogung. *Z Wiss Zool* 132, 105–134.
- Spits, C., Mateizel, I., Geens, M., Mertzani, A., Staessen, C., Vandeskelde, Y., Van der Elst, J., Liebaers, I., and Sermon, K. (2008). Recurrent chromosomal abnormalities in human embryonic stem cells. *Nat Biotechnol* 26, 1361–1363.
- Sridharan, R., Tchieu, J., Mason, M.J., Yachechko, R., Kuoy, E., Horvath, S., Zhou, Q., and Plath, K. (2009). Role of the murine reprogramming factors in the induction of pluripotency. *Cell* 136, 364–377.
- Stadtfeld, M., Apostolou, E., Akutsu, H., Fukuda, A., Follett, P., Natesan, S., Kono, T., Shioda, T., and Hochedlinger, K. (2010). Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. *Nature* 465, 175–181.
- Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., and Hochedlinger, K. (2008). Induced pluripotent stem cells generated without viral integration. *Science* 322, 945–949.
- Stojkovic, M., Stojkovic, P., Leary, C., Hall, V.J., Armstrong, L., Herbert, M., Nesbitt, M., Lako, M., and Murdoch, A. (2005). Derivation of a human blastocyst after heterologous nuclear transfer to donated oocytes. *Reprod Biomed Online* 11, 226–231.
- Subramanyam, D., Lamouille, S., Judson, R.L., Liu, J.Y., Bucay, N., Derynck, R., and Belloch, R. (2011). Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. *Nat Biotechnol* 29, 443–448.
- Szabo, E., Rampalli, S., Risueño, R.M., Schnerch, A., Mitchell, R., Fiebig-Comyn, A., Levadoux-Martin, M., and Bhatia, M. (2010). Direct conversion of human fibroblasts to multilineage blood progenitors. *Nature* 468, 521–526.
- Tada, M., Takahama, Y., Abe, K., Nakatsuji, N., and Tada, T. (2001). Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. *Curr Biol* 11, 1553–1558.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.
- Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663–676.
- Taranger, C.K., Noer, A., Sørensen, A.L., Håkeli, A.M., Boquest, A.C., and Collas, P. (2005). Induction of dedifferentiation, genome-wide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. *Mol Biol Cell* 16, 5719–5735.
- Teranishi, T., Tanaka, M., Kimoto, S., Ono, Y., Miyakoshi, K., Kono, T., and Yoshimura, Y. (2004). Rapid replacement of somatic linker histones with the oocyte-specific linker histone H1foo in nuclear transfer. *Dev Biol* 266, 76–86.
- Tesar, P.J., Chenoweth, J.G., Brook, F.A., Davies, T.J., Evans, E.P., Mack, D.L., Gardner, R.L., and McKay, R.D. (2007). New cell lines from mouse epiblast share defining features with human embryonic stem cells. *Nature* 448, 196–199.
- Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145–1147.
- Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., and Herrera, P.L. (2010). Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. *Nature* 464, 1149–1154.
- Tomioka, M., Nishimoto, M., Miyagi, S., Katayanagi, T., Fukui, N., Niwa, H., Muramatsu, M., and Okuda, A. (2002). Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. *Nucleic Acids Res* 30, 3202–3213.
- Tontonoz, P., Hu, E., and Spiegelman, B.M. (1994). Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell* 79, 1147–1156.
- Tsai, S.Y., Clavel, C., Kim, S., Ang, Y.S., Grisanti, L., Lee, D.F., Kelley, K., and Rendl, M. (2010). Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells. *Stem Cells* 28, 221–228.

- Tsonis, P.A., and Del Rio-Tsonis, K. (2004). Lens and retina regeneration: transdifferentiation, stem cells and clinical applications. *Exp Eye Res* 78, 161–172.
- Urbach, A., Bar-Nur, O., Daley, G.Q., and Benvenisty, N. (2010). Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. *Cell Stem Cell* 6, 407–411.
- Utikal, J., Polo, J.M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R.M., Khalil, A., Rheinwald, J.G., and Hochedlinger, K. (2009). Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. *Nature* 460, 1145–1148.
- Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Südhof, T.C., and Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* 463, 1035–1041.
- von Baer, K.E. (1828). *Über Entwicklungsgeschichte der Thier. Beobachtung und Reflexion (Königsberg, Bei den Gebrüderm Borntträger)*.
- Wang, T., Chen, K., Zeng, X., Yang, J., Wu, Y., Shi, X., Qin, B., Zeng, L., Esteban, M.A., Pan, G., et al. (2011a). The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. *Cell Stem Cell* 9, 575–587.
- Wang, W., Yang, J., Liu, H., Lu, D., Chen, X., Zenonos, Z., Campos, L.S., Rad, R., Guo, G., Zhang, S., et al. (2011b). Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. *Proc Natl Acad Sci U S A* 108, 18283–18288.
- Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., Ebina, W., Mandal, P.K., Smith, Z.D., Meissner, A., et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* 7, 618–630.
- Weintraub, H., Tapscott, S.J., Davis, R.L., Thayer, M.J., Adam, M.A., Lassar, A.B., and Miller, A.D. (1989). Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. *Proc Natl Acad Sci U S A* 86, 5434–5438.
- Willadsen, S.M. (1986). Nuclear transplantation in sheep embryos. *Nature* 320, 63–65.
- Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). Viable offspring derived from fetal and adult mammalian cells. *Nature* 385, 810–813.
- Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Mileikovsky, M., Hämmäläinen, R., Cowling, R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 458, 766–770.
- Wu, H., and Zhang, Y. (2011). Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. *Genes Dev* 25, 2436–2452.
- Xie, H., Ye, M., Feng, R., and Graf, T. (2004). Stepwise reprogramming of B cells into macrophages. *Cell* 117, 663–676.
- Ying, Q.L., Nichols, J., Evans, E.P., and Smith, A.G. (2002). Changing potency by spontaneous fusion. *Nature* 416, 545–548.
- Ying, Q.L., Wray, J., Nichols, J., Battle-Morera, L., Doble, B., Woodgett, J., Cohen, P., and Smith, A. (2008). The ground state of embryonic stem cell self-renewal. *Nature* 453, 519–523.
- Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T., and Yamanaka, S. (2009). Hypoxia enhances the generation of induced pluripotent stem cells. *Cell Stem Cell* 5, 237–241.
- Yu, J., Hu, K., Smuga-Otto, K., Tian, S., and Stewart, R. Slukvin, II, and Thomson, J.A. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 324, 797–801.
- Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. *Science (New York, NY)* 318, 1917–1920.
- Yusa, K., Rad, R., Takeda, J., and Bradley, A. (2009). Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. *Nat Methods* 6, 363–369.
- Yusa, K., Rashid, S.T., Strick-Marchand, H., Varela, I., Liu, P.Q., Paschon, D.E., Miranda, E., Ordóñez, A., Hannan, N.R., Rouhani, F.J., et al. (2011). Targeted gene correction of α 1-antitrypsin deficiency in induced pluripotent stem cells. *Nature* 478, 391–394.
- Zhang, J., Lian, Q., Zhu, G., Zhou, F., Sui, L., Tan, C., Mutalif, R.A., Navasankari, R., Zhang, Y., Tse, H.F., et al. (2011). A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. *Cell Stem Cell* 8, 31–45.
- Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. *Nature* 474, 212–215.
- Zhao, Y., Yin, X., Qin, H., Zhu, F., Liu, H., Yang, W., Zhang, Q., Xiang, C., Hou, P., Song, Z., et al. (2008). Two supporting factors greatly improve the efficiency of human iPSC generation. *Cell Stem Cell* 3, 475–479.
- Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 4, 381–384.
- Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., and Melton, D.A. (2008). In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. *Nature* 455, 627–632.